Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

GX-051

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Genexine

Drug class:

NK cell stimulant, IL-12 stimulant

Related drugs:

tavokinogene telsaplasmid (0)

pomalidomide (16)

AFM13/AB-101 (1)

cytotoxic lymphocyte-based cancer vaccine (0)

CAR-ITNK cells (0)

CAR-NK-CD19 cells (0)

CAR.70/IL15-transduced CB-NK cells (0)

CB CAR-NK019 (0)

CD123 targeted CAR-NK (0)

CD33/CLL1 dual CAR-NK cell (0)

CDH17 CAR-NK cell therapy (0)

CLDN6-CAR-NK cell therapy (0)

CYTO NK-102 (0)

DC vaccine for prostate cancer (0)

primed NK cell therapy (0)

Magicell-NK (0)

NK/γδ T cell-enriched cell therapy (0)

NK92-CD16-158V (0)

NKG2D CAR-NK cell therapy (0)

NKG2D-CAR-NK92 cells (0)

Super NK cell therapy (0)

TROP2-CAR-NK (0)

UD TGFbetai NK cells (0)

dualCAR-NK19/70 (0)

m-ceNK cells (0)

ADV/IL-12 gene therapy (0)

Ad-RTS-hIL-12 (0)

tavokinogene telsaplasmid (0)

›

Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer (NCT02079324)

Phase 1

Genexine, Inc.

Genexine, Inc.

Unknown status

Phase 1

Genexine, Inc.

Unknown status

Last update posted :

04/30/2015

Initiation :

03/01/2014

Primary completion :

09/01/2016

Completion :

09/01/2016

CD8 • CD4

|

GX-051